Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)

被引：0
|
作者：
Liam, C. K. [1 ]
Ahmad, A. Rozila [2 ]
Hsia, T. [3 ]
Li, J. Y. [4 ]
Le, X. [5 ]
Heymach, J. [5 ]
Yang, J. C. [6 ,7 ]
Soo, R. [8 ]
Zhang, Y. [9 ]
Kim, S. [10 ]
Shin, S. W. [11 ]
Johne, A. [12 ]
Karachaliou, N. [12 ]
Bruns, R. [13 ]
Ellers-Lenz, B. [13 ]
Wu, Y. [14 ,15 ]
机构：
[1] Univ Malaya, Med Ctr, Jalan Univ, Kuala Lumpur, Malaysia
[2] Beacon Int Specialist Ctr Sdn Bhd, Selangor, Malaysia
[3] China Med Univ Hosp, Taichung, Taiwan
[4] Hong Kong United Oncol Ctr, Hong Kong, Peoples R China
[5] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[8] Natl Univ Canc Inst, Singapore, Singapore
[9] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[10] Asan Med Ctr, Seoul, South Korea
[11] Korea Univ, Anam Hosp, Seoul, South Korea
[12] Merck Kgaa, Global Clin Dev, Darmstadt, Germany
[13] Merck Kgaa, Dept Biostat, Darmstadt, Germany
[14] Guangdong Prov PeopleS Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[15] Guangdong Acad Med Sci, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
MET inhibitor; tepotinib; MET amplification;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P51.01
引用
收藏
页码：S1118 / S1119
页数：2
相关论文
共 50 条
  • [1] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification (METamp): final analysis of INSIGHT
    Liam, Chong Kim
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 177 - 177
  • [2] Tepotinib plus Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
    OHara, R.
    Liam, C. Kin
    Ahmad, A. Rozila
    Hsia, T. -C.
    Zhou, J.
    Kim, D. -W.
    Soo, R. Andrew
    Cheng, Y.
    Lu, S.
    Shin, S. Won
    Yang, J. Chih-Hsin
    Zhang, Y.
    Zhao, J.
    Bruns, R.
    Johne, A.
    Wu, Y. -L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E6 - E7
  • [3] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [4] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
    Yang, J. C-H.
    Ellers-Lenz, B.
    Straub, J.
    Johne, A.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [6] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Itchins, Malinda
    Liam, Chong Kin
    Ahmad, Azura
    Hsia, Te-Chun
    Zhou, Janying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83
  • [7] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [8] Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Berghoff, Karin
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1879 - 1886
  • [9] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [10] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
12345